Bookmark

Add to MyYahoo RSS

Genomic Health News

News on Genomic Health (Ticker: GHDX) continually updated from thousands of sources around the net.

Friday Sep 12 | Freshnews

Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics

Genomic Health, Inc. today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment. "By providing quantitative information which has not been available with conventional measures, as demonstrated in this analysis, the Oncotype DX colon cancer test is likely to lead to both savings in direct medical costs and improved patient well-being," said Steven Alberts, M.D., chair, division of Medical Oncology at the Mayo Clinic, Rochester, Minn.

Comment?

Related Topix: Medicine, Cancer, Health, Colorectal Health, Colon Cancer, Startups, Oncology, Breast Cancer

Wed Sep 10, 2014

AmericanBankingNews.com

Genomic Health Coo G Bradley Cole Sells 4,700 Shares

Genomic Health COO G Bradley Cole unloaded 4,700 shares of Genomic Health stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $30.09, for a total value of $141,423.00.

Comment?

Related Topix: Startups

Tue Sep 09, 2014

Applied Clinical Trials

Genomic Health Announces Presentation of Positive Results from Latest ...

Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology 2014 Congress Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology 2014 Congress /PRNewswire/ -- Genomic Health, Inc. today announced that results from nine studies of Oncotype DX in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology 2014 Congress in - 30. Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, This new study demonstrates the test's ability to predict a rise in ... (more)

Comment?

Related Topix: Startups, Prostate Cancer, Health, Oncology, Medicine, Breast Cancer

Theflyonthewall.com

Genomic Health to present positive results from nine studies of Oncotype DX

Genomic Health to present positive results from nine studies of Oncotype DX Genomic Health announced that results from nine studies of Oncotype DX in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology, or ESMO, 2014 Congress in Madrid, September 26 - 30. Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, Rockville.

Comment?

Related Topix: Startups, Oncology, Medicine, Prostate Cancer, Health

Fri Sep 05, 2014

BioMed Central

Societal cost-effectiveness analysis of the 21-gene assay in...

Breast-cancer incidence and mortality have been increasing in Japan. Japanese-specific clinical validity and utility data for the 21-gene assay Breast Cancer Assay; Genomic Health, Inc., Redwood City, USA) are now available.

Comment?

Related Topix: Medicine, Health, Breast Cancer, Startups

Fri Aug 29, 2014

AmericanBankingNews.com

Genomic Health Receives Average Recommendation of "Hold" from Analysts

Genomic Health has received a consensus rating of "Hold" from the ten brokerages that are covering the stock, American Banking and Market News reports .

Comment?

Related Topix: Startups

Tue Aug 19, 2014

Freshnews

New England BiolabsA Introduces New Ribosomal RNA Depletion Technology from Genomic Health

New England Biolabs, Inc. ) today announced that NEB has exclusively in-licensed rights from Genomic Health, Inc. to its technology for the depletion of abundant RNAs, which is instrumental to performing sensitive RNA-seq experiments at a lower cost.

Comment?

Related Topix: Startups, Marketing

Sun Aug 17, 2014

AmericanBankingNews.com

Genomic Health EVP Steven Shak Unloads 13,348 Shares

Genomic Health EVP Steven Shak unloaded 13,348 shares of the stock in a transaction dated Thursday, August 14th.

Comment?

Related Topix: Startups

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••